Ovarian hyperstimulation syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:64739OMIM:608115N98.1
Who is this for?
Show terms as
1Active trials57Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can happen when a woman's ovaries overreact to fertility medications used during treatments like IVF (in vitro fertilization). These medications are designed to stimulate the ovaries to produce eggs, but sometimes the ovaries respond too strongly, causing them to swell and leak fluid into the belly and chest. This can range from mild discomfort to a serious, life-threatening condition. In mild cases, women may feel bloated, nauseous, or have some pelvic pain. In severe cases, large amounts of fluid can build up in the abdomen and lungs, the blood can become thicker and more prone to clotting, and the kidneys may be affected. Severe OHSS can lead to dangerous blood clots, kidney failure, or breathing problems. Most cases of OHSS are mild and get better on their own within one to two weeks. Severe cases require hospital care, including fluids given through a vein, draining excess fluid, and close monitoring. Women who become pregnant during a cycle where OHSS develops may have symptoms that last longer. With proper medical care, most women recover fully. Doctors now use careful monitoring and adjusted medication doses to reduce the risk of OHSS during fertility treatments.

Also known as:

Key symptoms:

Bloating and swollen bellyPelvic or abdominal pain or discomfortNausea and vomitingDiarrheaRapid weight gain (more than 2 pounds in 24 hours)Decreased urinationShortness of breath or difficulty breathingTight or uncomfortable feeling in the abdomenLeg pain or swelling (possible sign of blood clot)Dizziness or lightheadednessFeeling very thirsty despite drinking fluidsDark-colored urine

Clinical phenotype terms (17)— hover any for plain English
Ovarian cystHP:0000138Generalized edemaHP:0007430Enlarged polycystic ovariesHP:0008675HypovolemiaHP:0011106Increased serum testosterone levelHP:0030088Hemorrhagic ovarian cystHP:0012886Capillary leakHP:0030005Pulmonary edemaHP:0100598
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

3 events
Mar 2026150 IU vs. 225 IU FSH in Normal Responders: The OPTIMAL-DOSE Trial

American Hospital 2 Kosovo — PHASE3

TrialNOT YET RECRUITING
Jun 2025Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

Tanta University — PHASE2

TrialRECRUITING
Dec 2021Real-world Evidence on Follitropin Delta Individual Dosing

University of Luebeck

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Ovarian hyperstimulation syndrome.

1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

1 recruitingView all trials with filters →
Phase 21 trial
Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
Phase 2
Actively Recruiting
· Sites: Damietta, New Damietta · Age: 2035 yrs

Specialists

Showing 25 of 57View all specialists →
AM
Alfonso Bermejo, MD
Specialist
PI on 1 active trial
AM
Ashraf Moini, MD
Specialist
PI on 2 active trials
LM
Lawrence Engmann, MD
HARTFORD, CT
Specialist
PI on 3 active trials
CM
Claudio Benadiva, MD
FARMINGTON, CT
Specialist
PI on 1 active trial
AH
Ariel Hourvitz
Specialist
PI on 1 active trial
JM
Juan Giles, MD
Specialist
PI on 1 active trial
WM
Waleed M El-Khayat, M.D.
Specialist
PI on 1 active trial
MM
Marianne Sybille Hendricks, MBBS, MRCOG
KATY, TX
Specialist
PI on 1 active trial
MM
Marzieh Shiva, MD
Specialist
PI on 2 active trials
AM
ahmed saad, MD
Specialist
PI on 2 active trials
HF
Hosam Zaki, MSc, FRCOG
Specialist
PI on 1 active trial
HM
Hossam Elattar, MBBCH
Specialist
PI on 1 active trial
KB
khaled M Elqusi, BSc
Specialist
PI on 1 active trial
MM
Muhammad S Zeafan, MBBCH
Specialist
PI on 1 active trial
RP
Roberto Matorras, MD, PhD
Specialist
PI on 1 active trial
EM
Eniseh Tehraninejad, MD
Specialist
PI on 1 active trial
NM
Narges bagheri lankarani, MD
Specialist
PI on 1 active trial
AM
Ariane GOUTALAND, MD
Specialist
PI on 1 active trial
AP
Assunta Iuliano, MD, PhD
Specialist
PI on 1 active trial
FM
Fady I Sharara, M.D
Specialist
PI on 2 active trials
EM
Eman Elgendy, MD
Specialist
PI on 2 active trials
AM
Alexander G Swanton, MBBS MRCOG
Specialist
PI on 1 active trial
IA
Ismail E Khalifa, Ass.lecturer
Specialist
PI on 1 active trial
TM
Tim J Child, MA MD MRCOG
Specialist
PI on 1 active trial
SP
Sherif S Gafaar, Professor
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Ovarian hyperstimulation syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Ovarian hyperstimulation syndromeForum →

No community posts yet. Be the first to share your experience with Ovarian hyperstimulation syndrome.

Start the conversation →

Latest news about Ovarian hyperstimulation syndrome

Disease timeline:

New recruiting trial: Real-world Evidence on Follitropin Delta Individual Dosing

A new clinical trial is recruiting patients for Ovarian hyperstimulation syndrome

New recruiting trial: Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

A new clinical trial is recruiting patients for Ovarian hyperstimulation syndrome

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What is my personal risk level for developing OHSS based on my health history and test results?,What symptoms should make me call you immediately or go to the emergency room?,Should I weigh myself every day, and what weight gain should concern me?,Will having OHSS affect my chances of getting pregnant or my future fertility?,Can we adjust my medication protocol in future cycles to lower my risk of OHSS?,Is a freeze-all embryo strategy recommended for me to reduce OHSS risk?,How long should I expect to feel unwell, and when can I return to normal activities?

Common questions about Ovarian hyperstimulation syndrome

What is Ovarian hyperstimulation syndrome?

Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can happen when a woman's ovaries overreact to fertility medications used during treatments like IVF (in vitro fertilization). These medications are designed to stimulate the ovaries to produce eggs, but sometimes the ovaries respond too strongly, causing them to swell and leak fluid into the belly and chest. This can range from mild discomfort to a serious, life-threatening condition. In mild cases, women may feel bloated, nauseous, or have some pelvic pain. In severe cases, large amounts of fluid can build up in the abdome

How is Ovarian hyperstimulation syndrome inherited?

Ovarian hyperstimulation syndrome follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Ovarian hyperstimulation syndrome typically begin?

Typical onset of Ovarian hyperstimulation syndrome is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Ovarian hyperstimulation syndrome?

Yes — 1 recruiting clinical trial is currently listed for Ovarian hyperstimulation syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Ovarian hyperstimulation syndrome?

25 specialists and care centers treating Ovarian hyperstimulation syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.